Study of SHR-2173 for active lupus nephritis
Treatments studied
Part of Immune system & allergy, Kidney & urinary clinical trials.
This trial tests a new medicine called SHR-2173 for people with active lupus nephritis, a kidney inflammation caused by lupus. The goal is to see if it is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Ages 18 to 70
- Weight at least 40 kg and BMI between 16 and 28
- Diagnosed with lupus (SLE) by standard criteria
- Positive ANA or related antibodies in blood
- Kidney biopsy showing active lupus nephritis (class III, IV, or V) within the past year
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called SHR-2173 for people with primary membranous nephropathy, a kidney disease that causes protein leakage. The study aims to see if the drug is safe and effective, and it involves periodic injections and monitoring.
This study tests a new drug called HSK39297 combined with standard treatments (steroids and mycophenolate mofetil) for people with active lupus nephritis. It aims to see if the combination is safe and effective in reducing kidney inflammation.
This trial tests a new cell therapy (RY_SW01) for people with active lupus nephritis (kidney inflammation caused by lupus) who haven't responded well to standard treatments. It aims to see if the therapy can help control the disease.
This trial tests a new treatment, UB-VV410, for people with active systemic lupus erythematosus (SLE) or lupus nephritis (kidney inflammation caused by lupus) that hasn't responded to standard treatments. It aims to see if this therapy can help control the disease.
This trial tests a new drug called IPG11406 for people with active lupus nephritis, a type of kidney inflammation caused by lupus. It aims to see if the drug can help reduce kidney damage and improve symptoms.
This trial tests a new medicine called QLG1074 added to standard treatments for people with active lupus nephritis, a kidney problem caused by lupus. It aims to see if the combination helps control the disease better.
Hear when a new Active Lupus Nephritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.